Boston Scientific Is Poised to Accelerate Its Atrial Fibrillation Ablation Business in 2024

Boston Scientific has solidified its footing as one of three major cardiac device makers and significantly improved its innovation and operational chops. Boston remains a tough competitor—even a prolonged period of operational and management upheaval from 2006 to 2014 wasn't enough to permanently impair the underlying business and Boston's ability to develop and commercialize new technology platforms. Under CEO Michael Mahoney, the firm has focused on introducing meaningful innovation and leveraging its historically formidable sales and marketing resources.